Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570604 | 0.80 | ADORA2A (0.47) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL29487078 | 0.79 | XDH (0.55) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL1014920 | 0.79 | XDH (0.55) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL53863 | 0.79 | PLK4 (0.47) | ADORA2AXDHRETPI4KALRRK2 | |
| Benzene SCHEMBL25427466 | 0.76 | RET (0.52) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL888387 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL2629520 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL19891462 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1CDK2XDHRET | |
| SCHEMBL12398424 | 0.76 | PLK4 (0.36) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL31439112 | 0.76 | NOS1 (0.37) | CDK2XDHRETPI4KALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606564-B2 | Adenosine receptor antagonist compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| CN-116425756-B | Adenosine receptor antagonist compounds and uses thereof | 日东制药株式会社 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | UNIVERSITY OF WINDSOR (CA) | 2025-03-13 | — | — | US | disclosed |
| WO-2024242530-A1 | COMPOUND FOR NEUROPROTECTION, OR TREATING DISEASES RELATED TO ALPHA-SYNUCLEIN AND/OR NEURO-INFLAMMATION | YUNOVIA CO., LTD. (KR) | 2024-11-28 | — | — | WO | disclosed |
| CN-114829363-B | Adenosine receptor antagonist compounds | 日东制药株式会社 | 2024-10-01 | — | — | CN | disclosed |
| US-20240041888-A1 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-08 | — | — | US | disclosed |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6962991-B2 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-06-02 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040191824-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040116447-A1 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
| EP-1427743-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | Epoch Biosciences, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003022859-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | CDK4, CDK3, CDKN1A | ADORA2A 3543/4885ADORA1 4521/4885CDK2 4/4885 |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ADORA2A 4548/4885ADORA1 4784/4885CDK2 328/4885 |
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | ADORA2A 734/4885ADORA1 1524/4885CDK2 553/4885 |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | ADORA2A 734/4885ADORA1 1524/4885CDK2 553/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885CDK2 1109/4885 |
| US-20240041888-A1 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885CDK2 1323/4885 |
| US-12606564-B2 | Adenosine receptor antagonist compounds | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885CDK2 1768/4885 |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885CDK2 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.